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Background. Molecular rapid diagnostic tests, such as the microarray-based Verigene Gram-Negative Blood Culture Test (BC-GN), when performed in conjunction with antimicrobial stewardship, are associated with improved clinical outcomes in bloodstream infections (BSIs) . Optimal use of Verigene BC-GN to aid in clinical decision-making, however, can be hindered by a lack of confidence in results if patients have polymicrobial GN BSIs.
Methods. Blood culture data from patients tested by Verigene BC-GN from June 2015 -July 2016 from the Detroit Medical Center and University of Maryland Medical Center were retrospectively reviewed and evaluated for incidence of missed GNs in GN BSIs. Missed GNs entailed those not detected in the tested sample and those that grew in a separate complementary positive blood culture bottle collected but not tested using Verigene BC-GN. For blood culture sets with missed GNs, potential clinical significance was evaluated.
Results. A total of 1,003 sets of GN blood cultures were reviewed. Fifty-seven (5.6%) were determined to be polymicrobial GN BSIs by traditional microbiological culture methods. Verigene BC-GN did not identify one or more GNs in 37 cases (65% of polymicrobial GN BSIs; 3.7% of total GN BSIs.); 25 were missed by the probe in the tested culture and 12 where missed due to isolation in the complementary blood culture bottle that was not tested by Verigene BC-GN. While potentially inappropriate de-escalation of antibiotic therapy could have occurred in 18 (31.5%) of polymicrobial GN BSIs, this represented only 1.8% of total GN BSIs.
Conclusion. Current practices utilizing Verigene BC-GN can result in the omission of undetected GNs in over half of polymicrobial GN BSIs. These misses were a combination of technology and workflow limitations. The potential for inappropriate de-escalation of antibiotic therapy in the entire cohort, however, was infrequent (<2% of total cases). October 7, 2017: 12:30 PM Background. Early diagnosis of BSI and appropriate antimicrobials are crucial; additionally avoidance of overly broad antibiotics is important to curb the development of resistance. Rapid molecular approaches are costly and have spectrum limitations. In our prior pilot study simple phenotypic RDDDT provided accurate susceptibility data for GNB over 24 hours earlier than conventional methods. This follow up pilot study evaluated RDDDT plus prompt stewardship intervention to decrease the time to optimal antimicrobial therapy.
Disclosures
Methods. GNB positive blood cultures (BACTEC) were inoculated by expressed swab to MH agar plates. 12 antibiotic discs were applied. After at least 8 hr incubation, results in conjunction with MALDI-TOF speciation, were reported to EMR at 9am or 3pm. After review the ID Fellow contacted the primary MD to escalate, deescalate, or continue current antibiotics. Results of the RDDDT were compared with routine VITEK and assessed as complete agreement (CA) or as very major (VM), major (M), minor (MI) discrepancies. Times to susceptibility, RDDDT based antibiotic optimization, and VITEK reports were assessed. Time to VITEK based optimization was obtained from the prior baseline pilot study.
Results. 164 patients with GNB were evaluated. 1688 individual RDDDT readings, including 297 ESBL and 66 CRE were compared with VITEK. RDDDT had 85% CA and 0.4% VM, 2.3% M, 13% MI discrepancies. The median time from BC positivity to RDDDT report was 17.5 hours vs. 46 hours for VITEK. Of 164 patients, 162 were assessed clinically. Of those, 72 (44%) required antibiotic change with median time to optimization 21 hours based on RDDDT vs. 71 hours based on prior baseline VITEK.
Conclusion. RDDDT coupled with prompt stewardship intervention provided a safe and reliable strategy to improve time to antibiotic optimization with savings of ~2 days compared with standard VITEK reporting. Furthermore, RDDDT is simple and applicable worldwide, especially in resource limited areas. Background. Inappropriate initial antibiotic therapy (IIAT) for sepsis increases mortality. Fast diagnostic tests providing earlier identification (ID) of pathogens and antimicrobial susceptibility testing (AST) have the potential to improve mortality and antimicrobial stewardship. The Accelerate Pheno™ system (AXDX) is a newly FDA cleared fast diagnostic testing system that provides ID and AST for Gram-positive and Gram-negative bacteria (GNB) and ID for Candida bloodstream isolates.
Methods. From April 14, 2016 to March 13, 2017, blood cultures from unique patients in the emergency department or medical intensive care units at Barnes-Jewish Hospital signaling positive and Gram-stain positive for GNB or yeast were eligible for inclusion. Standard-of-care (SOC) diagnostics were conducted in parallel with AXDX, though AXDX could be delayed up to 8 hours depending on research technician availability. Differences in time to ID and AST between SOC and AXDX were determined. Clinical outcomes included appropriateness of initial empiric antimicrobial therapy, potential for early antimicrobial de-escalation with AXDX, and mortality.
Results. Of 341 screened blood cultures, 123 met inclusion criteria; 101 had organisms that were on-panel for AXDX, 88 GNB and 13 C. glabrata or C. albicans. For GNB, mean time from blood culture positivity to ID and AST using SOC was 19.8 and 53.5 hours, respectively, and 1.4 and 6.7 hours using AXDX (from time AXDX started). For Candida spp., mean time to ID was 33.1 hours for SOC, 1.4 hours for AXDX. Antimicrobial de-escalation was possible based on AXDX testing in 52.9% of patients with GNB infections. A total of 27 (27.3%) patients received IIAT. In-hospital mortality was higher (48.1%) in the IIAT group than in those receiving appropriate initial antibiotics (12.5%), P < 0.001. AXDX could have improved antimicrobial therapy in 89.8% of GNB and 92.3% of Candida spp. cases.
Conclusion. The Accelerate Pheno™ system is a novel fast diagnostic that significantly reduces the time to ID and AST for GNB and ID of Candida spp. bloodstream infections, with the potential to impact clinical outcomes. Prospective clinical trials are needed to evaluate the impact of this new system on clinical outcomes and antimicrobial stewardship.
Disclosures Background. Gram-negative bacteremia (GNB) is associated with significant morbidity and mortality, emphasizing the need for timely, effective antimicrobial therapy. In comparison to conventional diagnostic methods, Verigene® Blood-Culture Gram-Negative (VBC-GN) is a microarray rapid diagnostic test that identifies eight target GN organisms and six genetic resistance determinants. This study examined the potential clinical impact of VBC-GN coupled with a proposed antimicrobial stewardship (AMS)-derived treatment algorithm to guide timely, appropriate antimicrobial therapy in GNB.
Methods. Retrospective, single-center, study of adult patients (≥ 18 years) with GNB at University of Maryland Medical Center (UMMC) from September 2015 -May 2016. Patient clinical characteristics, co-morbidities, and antimicrobials administered were collected. Appropriateness of antimicrobial therapy was by in vitro susceptibility. Appropriateness of actual empiric antimicrobials received as standard care were compared with theoretical antimicrobials as guided by the UMMC AMS treatment algorithm. Two investigators (KCC and ELH) independently evaluated appropriateness of empiric and algorithm antimicrobial recommendations.
Results. 188 patients (median age 57.0 (IQR 46.5 -65.0) years) with GNB were included and 143 (76.1%) were positive for target GN organisms. Eight (4.3%) cases were GN polymicrobial, 8 (4.3%) were CTX-M positive. E. coli was the most common target GN organism (30.3%), and genitourinary was the most common source (29.3%). There was a good level of agreement between reviewers regarding appropriateness of empiric therapy (Kappa = 0.735) and algorithm recommendations (Kappa = 0.855). Overall, the proposed algorithm would have resulted in 88.4% of cases receiving appropriate antimicrobial therapy vs 78.1% actual empiric antimicrobials (P = 0.014). The AMS treatment algorithm would have resulted in 14.4% appropriate de-escalation, 4.8% inappropriate de-escalation, 5.3% appropriate escalation, and 16.0% unnecessary escalation.
Conclusion. Proposed antibiotics by AMS-derived treatment algorithm applied in conjunction with rapid diagnostic testing would result in a significantly higher proportion of patients receiving appropriate antimicrobial therapy vs. standard care. 
